Researchers reported a mussel‑inspired bioadhesive patch that selectively adheres to glioblastoma tissue and delivers cytotoxic agents to eliminate tumor cells in preclinical models. The platform leverages adhesive chemistries derived from marine mussel proteins to localize therapy to invasive tumor margins and reduce systemic exposure. The technology offers a surgical adjunct to target residual disease after resection and may address glioblastoma’s infiltrative biology. For clinical developers and device partners, the patch presents a potential route for combination with chemotherapeutics, immunotherapies, or local radiosensitizers and will require translational work on manufacturability, sterility and regulatory classification.